SystImmune-Bristol Myers Squibb (BMS) agreement for izalontamab brengitecan (iza-bren) development in 1L mTNBC ineligible for anti-PD-(L)1 therapies.

SystImmune received $250M in milestone payments from BMS after dosing of first patient in P2/3 IZABRIGHT-Breast01 trial of izalontamab brengitecan (iza-bren, BL-B01D1; EGFRxHER3-ADC) in 1L mTNBC ineligible for anti-PD-(L)1 therapies.

• SystImmune is further eligible to receive up to an additional $250M in contingent near-term milestone payments, with total potential payments of up to $7.1B upon clinical, regulatory, and sales performance milestones
  • BMS exclusively licensed iza-bren from SystImmune for co-development and ex-China commercialization in Dec 2023
• Chairman of SystImmune added that “robust data generated from our China-based trials have played an important role in accelerating development timelines and informing global strategy”